tert-butyl (3S,4S)-4-(2-oxopyrrolidin-1-yl)pyrrolidin-3-ylcarbamate | 1000303-32-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: tert-butyl (3S,4S)-4-(2-oxopyrrolidin-1-yl)pyrrolidin-3-ylcarbamate
• 英文别名: ((3'S,4'S)-2-oxo-[1,3']bipyrrolidinyl-4'-yl)carbamic acid tert-butyl ester；tert-butyl N-[(3S,4S)-4-(2-oxopyrrolidin-1-yl)pyrrolidin-3-yl]carbamate
• CAS: 1000303-32-1
• 化学式: C₁₃H₂₃N₃O₃
• 分子量: 269.344
• InChiKey: XMDDEQSZUGNLLY-UWVGGRQHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  70.7
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl (3S,4S)-4-(2-oxopyrrolidin-1-yl)pyrrolidin-3-ylcarbamate 在 三氟乙酸 作用下， 以 二氯甲烷 、 叔丁醇 为溶剂， 生成 C₁₈H₂₃N₇O₂
  参考文献：
  名称：

  1-((3S,4S)-4-Amino-1-(4-substituted-1,3,5-triazin-2-yl) pyrrolidin-3-yl)-5,5-difluoropiperidin-2-one inhibitors of DPP-4 for the treatment of type 2 diabetes

  摘要：

  A 3-amino-4-substituted pyrrolidine series of dipeptidyl peptidase IV (DPP-4) inhibitors was rapidly developed into a candidate series by identification of a polar valerolactam replacement for the lipophilic 2,4,5-trifluorophenyl pharmacophore. The addition of a gem-difluoro substituent to the lactam improved overall DPP-4 inhibition and an efficient asymmetric route to 3,4-diaminopyrrolidines was developed. Advanced profiling of a subset of analogs identified 5o with an acceptable human DPP-4 inhibition profile based on a rat PK/PD model and a projected human dose that was suitable for clinical development. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.055
• 作为产物：
  描述：

  1-[(3S,4S)-4-azido-1-benzylpyrrolidin-3-yl]pyrrolidin-2-one 在 palladium 10% on activated carbon 、 氢气 、 溶剂黄146 、 三苯基膦 作用下， 以 四氢呋喃 、 乙醇 、 水 、 乙酸乙酯 为溶剂， 50.0 ℃ 、517.12 kPa 条件下， 生成 tert-butyl (3S,4S)-4-(2-oxopyrrolidin-1-yl)pyrrolidin-3-ylcarbamate
  参考文献：
  名称：

  1-((3S,4S)-4-Amino-1-(4-substituted-1,3,5-triazin-2-yl) pyrrolidin-3-yl)-5,5-difluoropiperidin-2-one inhibitors of DPP-4 for the treatment of type 2 diabetes

  摘要：

  A 3-amino-4-substituted pyrrolidine series of dipeptidyl peptidase IV (DPP-4) inhibitors was rapidly developed into a candidate series by identification of a polar valerolactam replacement for the lipophilic 2,4,5-trifluorophenyl pharmacophore. The addition of a gem-difluoro substituent to the lactam improved overall DPP-4 inhibition and an efficient asymmetric route to 3,4-diaminopyrrolidines was developed. Advanced profiling of a subset of analogs identified 5o with an acceptable human DPP-4 inhibition profile based on a rat PK/PD model and a projected human dose that was suitable for clinical development. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.055

文献信息

• Substituted 3-Amino-Pyrrolidino-4-Lactams
  申请人：Piotrowski David W.

  公开号：US20070299076A1

  公开（公告）日：2007-12-27

  The invention provides compounds of formula (1), and the pharmaceutically acceptable salt thereof, wherein R 1 , n and R 2 are as described herein; compositions thereof; and uses thereof.

  这项发明提供了式（1）的化合物，以及其药用可接受的盐，其中R1、n和R2如本文所述；以及它们的组合物；以及它们的用途。
• [EN] COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE TROUBLES MÉTABOLIQUES
  申请人：PROSIDION LTD

  公开号：WO2010103334A1

  公开（公告）日：2010-09-16

  The present invention is directed to therapeutic compounds of the following formula (I) which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.

  本发明涉及具有以下式（I）的治疗化合物，其作为GPR119的激动剂具有活性，并可用于治疗包括2型糖尿病在内的代谢紊乱。
• Compounds for the Treatment of Metabolic Disorders
  申请人：Barba Oscar

  公开号：US20120059014A1

  公开（公告）日：2012-03-08

  The present invention is directed to therapeutic compounds of the following formula (I) which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.

  本发明涉及以下式(I)的治疗化合物，其具有作为GPR119激动剂的活性，可用于治疗代谢紊乱，包括II型糖尿病。
• US7485641B2
  申请人：——

  公开号：US7485641B2

  公开（公告）日：2009-02-03
• [EN] SUBSTITUTED 3 -AMINO- PYRR0LIDIN0-4 -LACTAMS AS DPP INHIBITORS<br/>[FR] 3-AMINO-PYRROLIDINO-4-LACTAMES SUBSTITUÉS
  申请人：PFIZER PROD INC

  公开号：WO2007148185A2

  公开（公告）日：2007-12-27

  [EN] The invention provides compounds of formula (1), and the pharmaceutically acceptable salt thereof, wherein R¹, n and R² are as described herein; compositions thereof and uses as DPP inhibitors.
  [FR] La présente invention concerne des composés de formule (1), ainsi que leurs sels de qualité pharmaceutique, R¹, n et R² étant tels que décrits dans la présente invention; la présente invention concerne également les compositions incluant lesdits composés ainsi que leurs applications.